|
KMID : 0370220200640010039
|
|
Yakhak Hoeji
2020 Volume.64 No. 1 p.39 ~ p.46
|
|
|
Impact of an Infliximab Biosimilar on Utilization and Expenditure of TNF-α inhibitors in South Korea
|
|
Noh Yun-Ha
Yoon Dong-Won
Shin Ju-Young
|
|
|
Abstract
|
|
|
|
Tumor necrosis factor α (TNF-α) inhibitor, biologics for immunosuppression, is widely used for various kindsof autoimmune disease and it has contributed to improving patients’ prognosis. With the expiration of its patent,biosimilars have emerged since September 2012 in South Korea. The competitive cost of biosimilars can lead to significantimpact on national health insurance finance. Thus, we aimed to estimate budget impact of the introduction of infliximabbiosimilar. Overall trends of utilization and expenditure among TNF-α inhibitors were presented using the National HealthInsurance Service-National Sample Cohort database, between May 2011 and December 2013. We conducted segmentedregression of interrupted time series analysis to evaluate impact of biosimilar introduction. Utilization and expenditure ofTNF-α inhibitor had generally increased during study period. Both quantitative usage and drug expenditure of infliximabbiosimilar have significantly increased, while those of etanercept have decreased, since the introduction of infliximabbiosimilar. The estimated expenditure savings due to the introduction of infliximab biosimilar was about 52 billion won,which greatly contributed to the reduction of the price of the infliximab original rather than the reduction from the use ofinfliximab biosimilar. In conclusion, the introduction of biosimilar presented substantial savings of expenditure. Furtherstudy will be needed to assess comprehensive impact of other biosimilars introduction.
|
|
|
KEYWORD
|
|
|
Biologics, biosimilar, TNF-α inhibitor, budget impact, utilization study
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
|
|